Mural Oncology PLC (MURA)
(Delayed Data from NSDQ)
$3.34 USD
+0.10 (3.09%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $3.36 +0.02 (0.60%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Balance Sheet
Fiscal Year End for Mural Oncology PLC falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 271 | 0 | -99,999 | -99,999 | -99,999 |
Receivables | 6 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 1 | 5 | NA | NA | NA |
Total Current Assets | 277 | 5 | NA | NA | NA |
Net Property & Equipment | 11 | 11 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 0 | 0 | NA | NA | NA |
Total Assets | 302 | 34 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 6 | 3 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 0 | NA | NA | NA |
Current Portion Capital Leases | 0 | 0 | NA | NA | NA |
Accrued Expenses | 17 | 33 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 29 | 42 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 0 | 0 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 0 | NA | NA | NA |
Minority Interest (Liabilities) | 0 | 0 | NA | NA | NA |
Total Liabilities | 38 | 55 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 295 | 0 | NA | NA | NA |
Retained Earnings | -31 | 0 | NA | NA | NA |
Other Equity | 0 | -22 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | 264 | -22 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 302 | 34 | NA | NA | NA |
Total Common Equity | 264 | -22 | 0 | 0 | 0 |
Shares Outstanding | 16.60 | NA | NA | NA | NA |
Book Value Per Share | 15.89 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Mural Oncology PLC falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 205 | 232 | 271 | 0 | 0 |
Receivables | 1 | 2 | 6 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 7 | 6 | 1 | 5 | 0 |
Total Current Assets | 213 | 239 | 277 | 5 | 0 |
Net Property & Equipment | 10 | 11 | 11 | 11 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 0 | 0 | 0 |
Total Assets | 235 | 264 | 302 | 30 | 0 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 2 | 6 | 4 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 16 | 14 | 17 | 17 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 25 | 21 | 29 | 26 | 0 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30 | 29 | 38 | 37 | 0 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 298 | 297 | 295 | 0 | 0 |
Retained Earnings | -93 | -62 | -31 | 0 | 0 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 205 | 235 | 264 | -7 | 0 |
Total Liabilities & Shareholder's Equity | 235 | 264 | 302 | 30 | 0 |
Total Common Equity | 205 | 235 | 264 | -7 | 0 |
Shares Outstanding | 16.90 | 16.90 | 16.60 | NA | NA |
Book Value Per Share | 12.10 | 13.90 | 15.89 | 0.00 | 0.00 |